Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may guide ovarian cancer maintenance therapy

NCT ID NCT05027828

Knowledge-focused Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a blood test for circulating tumor DNA (ctDNA) can help predict how well PARP inhibitor maintenance therapy works in women with high-grade serous ovarian cancer. Researchers will collect blood samples before surgery, after chemotherapy, during targeted therapy, and at disease progression. The goal is to see if ctDNA levels can guide treatment decisions and detect recurrence early. The study plans to enroll 100 participants who are newly diagnosed and receiving first-line treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a blood test that helps doctors choose the right maintenance therapy for ovarian cancer and catch recurrence earlier.
What could go wrong
This is an observational study, not a treatment trial. It is still recruiting and results may not change practice immediately. The approach may not prove reliable for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Newly-diagnosed and treated patients with high-grade serous ovarian cancer who will receive PARP inhibitors as first-line maintenance therapy after surgery and traditional chemotherapy.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ovarian cancer first diagnosed and treated; 2. Pathologically confirmed as epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer; 3. The stage of the disease is II-IV, and surgery will be performed after evaluation; 4. Age ≥ 18 years old; 5. Subjects and their families fully understand the research plan and sign an informed consent form. Exclusion Criteria: 1. Pathologically confirmed as non-epithelial ovarian cancer; 2. Surgical treatment cannot be performed after evaluation; 3. Malignant tumors found in other parts of the study were found within five years before enrollment or at the time of enrollment; 4. Patients who do not agree to use clinical first-line targeted drugs; 5. Severe mental illness; 6. Severe cardiovascular disease, uncontrollable infection, or other uncontrollable comorbid diseases.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Circulating tumor DNA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Circulating tumor DNA High grade serous ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.